(3S,5S,E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid

Catalog No. :
ACZISV959
CAS No. :
688735-41-3
Molecular Formula :
C25H24FNO4
Molecular Weight :
421.47

IUPAC Name:(3S,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid

(3S,5S,E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$1239.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(3S,5S,E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid
IUPAC Name(3S,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid
Molecular FormulaC25H24FNO4
Molecular Weight421.47
SMILESO=C(O)C[C@@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4CC4
InChI KeyVGYFMXBACGZSIL-VVZAMHAXSA-N
Synonym(3S,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid;(3S,5S,E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid;4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid;(E,3S,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid;6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3S,5S,6E)-;(3S,5S,6E)-Pitavastatin
CAS No.688735-41-3

Synthetic Route by SureRoute

1. ACZISV959 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZISV959 route product structure diagram
    ACZISV959688735-41-3
Inquiry

2. ACZISV959 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZISV959 route product structure diagram
    ACZISV959688735-41-3
Inquiry

Comments (0)